C4 Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | $45.8M |
| Operating income | -$115.2M | -$119.6M | -$139.0M | -$129.5M | -$82.1M |
| Operating expenses | $151.2M | $155.2M | $159.8M | $160.6M | $127.9M |
| Cash from operations | -$98.7M | -$65.2M | -$106.8M | -$105.9M | -$87.0M |
| Capital expenditure | $607,000 | $180,000 | $1.7M | $5.5M | $1.3M |
| Free cash flow | -$99.3M | -$65.3M | -$108.5M | -$111.4M | -$88.2M |
| Share repurchases | $193,000 | $194,000 | $110,000 | $0 | — |
| Total assets | $359.1M | $349.6M | $376.5M | $430.8M | $506.8M |
| Total liabilities | $102.5M | $133.6M | $130.3M | $141.6M | $117.2M |
| Total debt | — | — | — | $12.5M | $12.5M |
Shares outstanding 110.6M · Free float 92.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.